Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Potenza Therapeutics Inc.

http://potenzatherapeutics.com/index.php

Latest From Potenza Therapeutics Inc.

Pharma Outlook 2022: What Next After A Year Of Innovation And Growth?

The biopharma industry broke records again in 2021 with the amount of money raised for drug development. After a year of rapid growth, what will 2022 bring for market dynamics and R&D catalysts in biopharma?

Outlook 2022 Growth

New Daiichi Structure Strengthens Oncology Focus

Japanese firm creates new US-based global organization that reaffirms strategic focus on oncology as main pillar of mid-term growth.

Business Strategies Cancer

Japan Pharma Pandemic Impact: Win Some, Lose Some

As Japanese pharma companies report quarterly results, the multi-faceted impact of the ongoing coronavirus pandemic on business operations has become clearer. The good news is that it’s been limited so far and the situation has been generally improving.

Japan Commercial

Japan 2010s In Review: Specialize, Focus, Innovate

Reimbursement issues continued to dominate the policy sphere in Japan during the last decade, while new forms of therapy benefited from positive regulatory reforms. Meanwhile, consolidation and specialization were major threads running through the corporate sector.

Japan Reimbursement
See All

Company Information

UsernamePublicRestriction

Register